ISRCTN88164211 https://doi.org/10.1186/ISRCTN88164211

# Pathophysiology of Dupuytren's Contracture

| Submission date | Recruitment status | [ ] Prospectively registered |
|---|---|---|
| 11/08/2010 | No longer recruiting | [ ] Protocol |
| **Registration date** | **Overall study status** | [ ] Statistical analysis plan |
| 11/08/2010 | Completed | [ ] Results |
| **Last Edited** | **Condition category** | [ ] Individual participant data |
| 18/04/2017 | Musculoskeletal Diseases | [ ] Record updated in last year |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Mr Liaquat Suleman-Verjee

**Contact details**
Imperial College London
Kennedy Institute of Rheumatology Division
65 Aspenlea Road
London
United Kingdom
W6 8LH

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**
6585

## Study information

**Scientific Title**

Pathophysiology of Dupuytren's Contracture

## Study objectives
Dupuytren's disease is a common inheritable disorder, mainly affecting the hand. The digits develop progressive flexion contractures and hand function is significantly impaired. The current mainstay of treatment is surgical excision of the affected tissues but recurrence following excision is seen in approximately 40% of patients. Replacing the palmar skin with grafts obtained from a non-palmar site on the body virtually abolishes recurrence. Based on this well-established surgical observation, we have developed a novel in vitro model that replicates these interactions between skin cells and the contractile cells responsible for Dupuytren's disease. We have also identified a molecule (tenascin-C) that may control the signalling between these cell types.

## Ethics approval required
Old ethics approval format

## Ethics approval(s)
MREC approved, ref: 06/Q0403/95

## Study design
Multicentre non-randomised interventional treatment trial

## Primary study design
Interventional

## Secondary study design
Non randomised study

## Study setting(s)
GP practice

## Study type(s)
Treatment

## Participant information sheet
Not available in web format, please use the contact details to request a patient information sheet

## Health condition(s) or problem(s) studied
Topic: Generic Health Relevance and Cross Cutting Themes; Subtopic: Generic Health Relevance (all Subtopics); Disease: Surgery

## Interventions
Elucidate the exact role of tenascin-C in Dupuytren's disease

## Intervention Type
Other

## Phase
Not Specified

### Primary outcome measure
Develop candidate therapeutic target to provide non-surgical intervention to modulate the disease

### Secondary outcome measures
Not provided at time of registration

### Overall study start date
02/11/2006

### Completion date
31/07/2011

## Eligibility

### Key inclusion criteria
Not provided at time of registration

### Participant type(s)
Patient

### Age group
Not Specified

### Sex
Not Specified

### Target number of participants
Planned sample size: 90

### Key exclusion criteria
Not provided at time of registration

### Date of first enrolment
02/11/2006

### Date of final enrolment
31/07/2011

## Locations

### Countries of recruitment
England

United Kingdom

### Study participating centre

**Imperial College London**
London
United Kingdom
W6 8LH

# Sponsor information

**Organisation**
Royal College of Surgeons of England (UK)

**Sponsor details**
35-43 Lincoln's Inn Fields
London
England
United Kingdom
WC2A 3PE

**Sponsor type**
University/education

**Website**
http://www.rcseng.ac.uk/

**ROR**
https://ror.org/02qrg5a24

# Funder(s)

**Funder type**
Charity

**Funder Name**
Healing Foundation

**Alternative Name(s)**

**Funding Body Type**
Private sector organisation

**Funding Body Subtype**
Other non-profit organizations

**Location**
United Kingdom

# Results and Publications

**Publication and dissemination plan**
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**
Not provided at time of registration